X4 Pharmaceuticals presents mavorixafor Phase 3 trial plans for primary chronic neutropenia
XFOR•X4 Pharmaceuticals plans to enroll 126 patients in its Phase 3 4WARD trial by Q4 2026, with topline data expected in Q1 2028 and potential U.S. FDA approval targeted for late 2028 or early 2029.
1. Trial timelines
At its virtual investor day, X4 Pharmaceuticals outlined plans for the 4WARD trial of mavorixafor in primary chronic neutropenia. The company targets first patient visits in Q1 2027 for its Phase 2b 4STEPS trial, which will evaluate G-CSF dose reduction with mavorixafor and plans to enroll approximately 25 patients; topline data are expected in the first half of 2028.
